INTRODUCTION
============

For the treatment of low-grade mucosa-associated lymphoid tissue (MALT)-type gastric B-cell lymphoma (MALT lymphoma), eradication of *Helicobacter pylori* (*H. pylori*) is the gold standard, and chemotherapy with anticancer agents and radiation therapy have been used as adjuvant treatments, but about 10% of the cases cannot be cured with these treatments. The monoclonal antibody against CD20, rituximab alone or rituximab with a combination of chemotherapy agents or radiotherapy has been reported to be very promising \[[@R1]\], though cases resistant to rituximab have still been reported and new treatments are awaited \[[@R2]\]. In our research, we have used several antiangiogenic agents for the treatment of *Helicobacter heilmannii (H. heilmannii)*-induced mouse gastric MALT lymphoma. 

In this paper, we discuss the present putative pathogenesis, pathological characteristics and possible new pharmacotherapy of gastric MALT lymphoma.

Pathogenesis of the Gastric MALT Lymphoma
-----------------------------------------

The pathophysiology of gastric MALT lymphoma is one of the most important points yet to be clarified in the study of *Helicobacter-*related upper gastrointestinal diseases. Many reports have pointed out the strong relation of *H. pylori* to the pathogenesis of MALT lymphoma. The predominantly antral localization of gastric MALT lymphoma is the result of the distribution of reactive MALT in response to *H. pylori* infection \[[@R3]\], which provides an antigenic drive for the growth of these tumors, but the precise mechanism for gastric MALT lymphoma growth is still under investigation.

Stolte *et al*. \[[@R4]\] pointed out the stronger presence of *H.* *heilmannii* than *H. pylori* in human MALT lymphoma cases based on the histological study. This bacillus exhibits a zoonotic infection pattern and is sometimes detected in domestic animals, such as cats, dogs, cows and pigs, as well as in humans. We also detected high *H. heilmannii* positivity in human cases of gastric MALT lymphoma by PCR analysis \[[@R5]\]. In addition, our recent study has revealed that oral infection of *H. heilmannii* from cynomolgus monkeys induced gastric low-grade MALT lymphoma in almost all C57BL/6 mice after a period of six months \[[@R6]\], suggesting the significance of *H. heilmannii* as well as *H. pylori* in the formation of gastric MALT lymphoma.

Pathological Characteristics of Gastric MALT Lymphoma
-----------------------------------------------------

Gastric MALT lymphoma is characterized by an accumulation of B lymphocytes along with the destruction of glandular elements and the presence of lymphoepithelial lesions (Fig. **[1](#F1){ref-type="fig"}**) \[[@R6]\]. Electron microscopic observation revealed numerous *H. heilmannii*bacilli mostly in the fundic glandular lumen as well as in the intracellular canaliculi, and the cytoplasm of intact and damaged parietal cells (Fig. **[2](#F2){ref-type="fig"}**).

Angiogenesis and Lymphangiogenesis of Gastric MALT Lymphoma
-----------------------------------------------------------

Markedly enhanced angiogenesis is another pathological characteristic of this tumor. Immunohistochemical methods using the vascular endothelial antibody CD31 and anti-lymphatic endothelial antibodies prox-1 and podoplanin (Figs. **[3](#F3){ref-type="fig"}**, **[4](#F4){ref-type="fig"}**, **[5](#F5){ref-type="fig"}**) have shown that this tumor has an irregular microvascular network \[[@R7],[@R8]\]. VEGF-A, VEGF-C and related receptors Flt-1, Flk-1 and Flt-4 were found to be richly distributed in and near the MALT lymphoma \[[@R9]\]. In this respect, the relation of the MALT lymphoma to lymphangiogenesis as shown by the localization of Flt-4, prox-1, podoplanin and VEGF-C is also very important, because it influences the metastasis of the tumors and prognosis of the bearing person or animal, and this could be one of the targets of the pharmacotherapy for gastric MALT lymphoma.

Regarding the localization of the lymphatics in the fundic mucosa, Sugito *et al*. \[[@R10]\] reported that lymphatic vessels existed only in the base of the mucosa, submucosa and muscular layer as a plexus and not in the upper or middle portion of the mucosa. In our experiment, the formation of MALT lymphoma was accompanied by lymphatic vessel formation with Flt-4 immunoreactivity in the marginal area of the MALT lymphoma. As to the origin of these newly formed lymphatic vessels, the extension from the preexisting lymphatic vessels in the base of the mucosa is most probable. On the other hand, some reports have pointed out that the sprouting of lymphatic endothelial cells with strong Flt-4 activity was recognized from the venules \[[@R11]\].

New Treatment of Gastric MALT Lymphoma
--------------------------------------

At present, the first choice of gastric MALT lymphoma treatment is the eradication by triple therapy applied to *H. pylori*, i.e., the combination of two kinds of antibiotics and proton pump inhibitors for several days, but this regimen generally shows a less than 70% response rate, due to *H. pylori* resistance to antibiotics, especially clarithromycin, chromosomal aberration and the presence of perigastric lymph nodes \[[@R12]\]. In our experiment, some strains of *H. heilmannii* were also found to be resistant to standard triple therapy \[[@R13]\]. As mentioned above, the most promising molecular target agent for the treatment of MALT lymphoma is rituximab, the monoclonal antibody against CD20, but several resistant cases against rituximab have already been reported \[[@R2]\]. Based on our histochemical analysis, the antiangiogenic therapy could be effective. The antiangiogenic agents available clinically or experimentally could be classified as shown in Table **[1](#T1){ref-type="table"}**. We selected two agents, VEGF-receptor antibodies \[[@R14]\] and a COX-2 inhibitor, celecoxib \[[@R9]\], for the treatment of mouse gastric MALT lymphoma.

Effect of VEGF Receptor Antibodies on Gastric MALT Lymphoma
-----------------------------------------------------------

The *H. heilmannii*-infected mice were divided into the following four groups: phosphate-buffered saline group, Flt-4 group, Flt-4 and Flt-1group, and Flt-4 and Flk-1 group. Rabbit polyclonal antibodies against Flt-1, Flk-1and Flt-4 (50 mg/mouse) (R&D Systems, MN, USA) were intraperitoneally administered. Stereomicroscopic study revealed that the administration of the Flt-4 and Flt-1 antibodies significantly reduced the occupied surface area of the lymphoma in the fundic portion of the mouse stomach as well as the average size of tumors (Fig. **[6](#F6){ref-type="fig"}**). In double staining with caspase-3 and prox-1, some of the apoptotic cells were shown to be lymphatic endothelial cells (Fig. **[7](#F7){ref-type="fig"}**).

Clinically, bevacizumab \[[@R15]\] and aflibercept \[[@R16]\] have been reported to be very promising in the therapy for cancer and neovascular age-related muscular degeneration. Bevacizumab is a humanized anti-human VEGF-A monoclonal antibody; as it has been shown to be ineffective against murine VEGF-A, it could not be applied to our study.

In summary, a VEGF-mediated mechanism was shown to play an important role in the expansion of MALT lymphoma tissue through angiogenesis and lymphangiogenesis, and its inhibition by a receptor antibody showed a significant effect. 

Effect of Celecoxib, a COX-2 Antagonist, on Gastric MALT Lymphoma
-----------------------------------------------------------------

Selective cyclooxygenase-2 (COX-2) inhibitors have been reported to suppress tumor expansion through anti-angiogenic activity in various kinds of malignancy \[[@R17]\]. In gastric MALT lymphoma, COX-2 and microsomal prostaglandin E synthase-1 (mPGES-1), the rate-limiting enzyme of prostaglandin E synthase, were observed by indirect immunohistochemical methods and confocal laser microscopy. Both the COX-2 and mPGES-1 immunoreactivities were markedly recognized on the apical region of the MALT lymphoma (Fig. **[8](#F8){ref-type="fig"}**).

We also investigated the effect of celecoxib, one of the selective COX-2 inhibitors, on tumor expansion. Hh-infected mice were

divided into the vehicle and celecoxib-administered groups. In the celecoxib-administered group, 30 or 100 mg/kg of the agents were administered twice a day through oral intubation throughout the experiment. One, two and four weeks after the start of the administration, the area in the fundic region occupied by the tumor was estimated. The addition of celecoxib decreased the tumor occupant area in the fundic mucosa as well as the B220 mRNA (Figs. **[9](#F9){ref-type="fig"}**, **[10](#F10){ref-type="fig"}**). The immunoreactivity of the CD31 and Prox-1 declined markedly. VEGF-A and VEGF-C content in the fundic mucosa was significantly decreased four weeks after the start of administration. These data show the the effect of celecoxib was exerted, at least partly, through its angiogenic activity.

New Agents for MALT Lymphoma Suppression
----------------------------------------

Recently, many factors generally thought to be irrelevant to angiogenesis have been found instead to be closely related to angiogenesis. In interleukin (IL)-10 knockout mice, the induction of MALT lymphoma was not observed, and this phenomenon was related to the suppression of angiogenesis. Saito *et al* recently reported the relation of microRNA to the formation of gastric MALT lymphoma \[[@R18]\]. In that study, *miR-142-5p* and *miR-155* were found to be overexpressed in MALT lymphoma, and these microRNAs are related to suppression of the proapoptotic gene *TP53INP1.*This suggests the possibility of other anti-microRNA-related compounds as chemotherapeutic agents against gastric MALT lymphoma.

The reevaluation of pharmacological therapy from the viewpoint of angiogenesis is an important subject for future study.
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![Light and electron microscopic observations of lymphoid follicles and lymphoepithelial lesions.\
a: Lymphoid follicle (L) observed in the fundic mucosa of a mouse infected for 6 months. Toluidine blue-stained Epon (x100).\
b: Lymphoepithelial lesion in the stomach of a mouse infected for 6 months. Toluidine blue-stained Epon (x600).\
c: Invasion of a lymphocyte between fundic glandular cells in a mouse infected for 6 months (x3000).\
d: Accumulation of centrocyte-like cells in a lymphoid follicle (x2000).](CPD-20-1097_F1){#F1}

![The localization of *H. heilmannii* by *in situ* hybridization, immunohistochemistry and electron microscopic cytochemistry.\
**a**, **b**: Many reactive bacilli were recognized by *in situ* hybridization at the luminal side of the body of the fundic gland (**a**). No reaction was detected with the use of a sense probe (**b**). (x800).\
**c**, **d**: Indirect fluorescent immunohistochemistry using anti-Hp polyclonal antibody revealed immunoreactive bacilli at the luminal side of the body of the fundic gland (**c**). Alexa-phalloidin fluorescence (**d**) revealed that the localization of bacilli coincided approximately with that of f-actin-rich parietal cells (x800).\
**e**, **f**, **g**: Electron microscopy revealed the presence of extremely numerous bacilli near (**e**, **f**) and in (**g**) the intracellular canaliculi (**e**: x2000; **f**, **g**: x6000).\
h, i: Some bacilli-disrupted epithelial cells. An adjacent parietal cell was destroyed (arrowhead) (h: x2000; i: x6000).](CPD-20-1097_F2){#F2}

![Electron micrographs showing the microvessels in and near the MALT lymphoma in *H. heilmannii*-administered mice.\
**a**: A venule (V) within the MALT lymphoma (x3000).\
**b**: A capillary (C) with irregular endothelial cells with rich cytoplasm (x3000).\
**c**: A capillary (C) surrounded with pericyte with electron-dense cytoplasm (x4000).\
**d**: A lymph capillary (L) within the MALT lymphoma (x4000).](CPD-20-1097_F3){#F3}

![Prox-1 immunoreactivity and 5' nucleotidase enzyme cytochemistry in the control and *H. heilmannii*-treated mouse fundic mucosa.\
**a**, **b**: In the control mouse fundic mucosa, prox-1 immunoreactivity was detected near the muscularis mucosae (MM) and in the lamina propria mucosae between the fundic glands. (**a**: x400, **b**: x200)\
**c**, **d**: In the *H. heilmannii*-administered mouse fundic mucosa, prox-1 immunoreactivity was recognized within the lymphoma. (**c**: x 100, **d**: x1000)\
**e**: By electron microscopic enzyme cytochemistry of 5' nucleotidase, the reaction products were recognized on the abluminal surface of the endothelial cells. (x4000)](CPD-20-1097_F4){#F4}

![VEGF-C and Flt-4 Immunoreactivity in the *H. heilmannii*-treated mouse fundic mucosa.\
**a**, **b**: VEGF-C immunoreactivity is recognized in the marginal area of the lymphoma. (**a**: x200, **b**: x400)\
**c**, **d**: Flt-1 immunoreactivity is found mostly in the marginal area of the lymphoma. (**c**: x200, **d**: x 1000)](CPD-20-1097_F5){#F5}

![Statistical analysis of the effect of Flt-4 on MALT lymphoma.\
**a**: Time course of the change of surface area occupied by MALT lymphoma through stereomicroscopic observation. Mixed administration of Flt-4 and Flk-1 significantly decreased the occupied area in four weeks. A P value less than 0.05 denoted the presence of a statistically significant difference. \
**b**: Time course of the size of MALT lymphoma by light microscopic observation.\
The tumor showed a tendency to shrink, especially following the mixed administration of Flt-4 and Flk-1. \
**c**: Time course of the caspase-3-immunoreactive cells within the tumor by confocal laser microscopy.\
The number of caspase-3-immunoreactive cells in MALT lymphoma was greatest one week after in all Flt-1 administered group.](CPD-20-1097_F6){#F6}

![Caspase-3 and prox-1 immunoreactivities in *H. heilmannii*-infected and Flt-4- and Flk-1-administered mice.\
**a**: One week after the administration, many cells within the MALT lymphoma showed positive immunoreactivity against caspase-3.(x200)\
**b**: Three weeks after the administration, the lymphoma became very small and few caspase-3-immunoreactive cells were observed in the lymphoma. (x400)\
**c**-**e**: In double staining with caspase-3 and prox-1, some of the prox-1-positive cells were found to be caspase-3 immunoreactive (arrow).\
**c**: Prox-1 immunoreactivity, d: caspase-3 immunoreactivity, e: merged view of c and d. (x1000)](CPD-20-1097_F7){#F7}

![COX-2 and mPGES-1 immunohistochemistry in gastric MALT lymphoma. The immunoreactivities of COX-2 (a) and mPGES-1 (b) were mark-edly recognized in the interstitial cells in the lamina propria mucosae surrounding the MALT lymphoma tissues (L). (x200)](CPD-20-1097_F8){#F8}

![Alteration of the tumor occupant area after celecoxib administration.\
Four weeks after celecoxib administration (100 mg/kg b.w.), the tumor occupant area was significantly decreased.](CPD-20-1097_F9){#F9}

![Alteration of the B220 mRNA level after celecoxib administration\
Four weeks after celecoxib administration, the B220 mRNA level was significantly decreased.](CPD-20-1097_F10){#F10}

  Classes of inhibitors              Kinds                              Examples of Drugs
  ---------------------------------- ---------------------------------- -----------------------------
  VEGF antagonists                   anti-VEGF-mAb                      Bebacizumab
                                     VEGF trap                          s-Flt-1, s-Flk-1
                                     other VEGF inhibitors              NM-3
  Broad GF inhibitors                Inhibitors of heparin-GF binding   Suraimn
  VEGF receptor antagonists          anti-VEGF-R2 mAbs                  IMC-1C11
                                     VEGF-R2 inhibitor                  sumaxanib
                                     VEGF-R mRNA ribozyme               Angiozyme
  PDGF receptor antagonists          PDGF-R inhibitors                  Gleevec
  Endothelin R (lectin) inhibitors                                      GBC-590
  Integrin angatonists               anti-alphaVbeta3 mAbs              LM-609
                                     alpha5beta1 antagonist             Endostatin
  Signaling inhitibitors             PKC inhibitors                     PKC-412
                                     PKA inhibitors                     AS PKAI
                                     MAPK ihbibitors                    PD98039
                                     mTOR inhibitors                    Rapamycin
  Anti-inflammatory drugs            NSAIDs                             Indomethacin
                                     COX-2 inhibitors                   celecoxib, rofecoxib, NS398
                                     Inhibitor of Mf activation         thalidomide
  Proteinase inhibitors              MMP inhibitors                     Batimastat
                                     PA inhibitors                      PAI-1
                                     Heparinase                         PI-88
  Cototoxic agents                   Pro-apoptotic factors              TNF
                                     Tubulin-binding agents             combretastatin
  HSP inhibitors                     HSP90 inhibitor                    17-AAG
